MX364528B - Withanolides useful for the treatment of neurodegenerative diseases. - Google Patents

Withanolides useful for the treatment of neurodegenerative diseases.

Info

Publication number
MX364528B
MX364528B MX2016006544A MX2016006544A MX364528B MX 364528 B MX364528 B MX 364528B MX 2016006544 A MX2016006544 A MX 2016006544A MX 2016006544 A MX2016006544 A MX 2016006544A MX 364528 B MX364528 B MX 364528B
Authority
MX
Mexico
Prior art keywords
neurodegenerative diseases
withanolides
useful
treatment
formula
Prior art date
Application number
MX2016006544A
Other languages
Spanish (es)
Other versions
MX2016006544A (en
Inventor
A Shaw Anthony
H Chan Agnes
Pierre Julien Jean-
Original Assignee
Imstar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imstar Therapeutics Inc filed Critical Imstar Therapeutics Inc
Publication of MX2016006544A publication Critical patent/MX2016006544A/en
Publication of MX364528B publication Critical patent/MX364528B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Provided herein are synthetic analogs of withanolide natural products of formula (I), wherein R1-R4 are as defined herein, and their pharmaceutical uses in treating neurodegenerative diseases.
MX2016006544A 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases. MX364528B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361908455P 2013-11-25 2013-11-25
PCT/US2014/067436 WO2015077780A1 (en) 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
MX2016006544A MX2016006544A (en) 2016-12-12
MX364528B true MX364528B (en) 2019-04-30

Family

ID=52023694

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006544A MX364528B (en) 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases.

Country Status (14)

Country Link
US (1) US10351590B2 (en)
EP (1) EP3074414B1 (en)
JP (1) JP6517833B2 (en)
KR (1) KR20160137945A (en)
CN (1) CN105940010B (en)
AU (1) AU2014352629B2 (en)
BR (1) BR112016012002A2 (en)
CA (1) CA2931064C (en)
ES (1) ES2728870T3 (en)
MX (1) MX364528B (en)
PL (1) PL3074414T3 (en)
TR (1) TR201905218T4 (en)
WO (1) WO2015077780A1 (en)
ZA (1) ZA201603117B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210087222A1 (en) * 2017-12-11 2021-03-25 Ethnodyne Compounds for treating neurodegenerative disorders
WO2019116069A1 (en) * 2017-12-11 2019-06-20 Ethnodyne Compounds for treating neurodegenerative disorders
EP3724207A1 (en) * 2017-12-11 2020-10-21 Ethnodyne Compounds for treating neurodegenerative disorders
CN111377994A (en) * 2018-12-28 2020-07-07 南开大学 Seven withanolides compounds from cape gooseberry and preparation method and application thereof
CN116063373A (en) * 2023-02-14 2023-05-05 广西医科大学 Process for preparing natural product 27-Deoxywithaferin A

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010030395A2 (en) 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Withaferin a analogs and uses thereof
WO2010053655A2 (en) * 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
US8598339B2 (en) * 2011-02-01 2013-12-03 University Of Kansas Withanolide isolated from Physalis longifolia and analogs and methods of use thereof
EP2723866B1 (en) * 2011-06-22 2018-03-28 Universite Laval Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease

Also Published As

Publication number Publication date
CN105940010A (en) 2016-09-14
EP3074414B1 (en) 2019-01-09
CN105940010B (en) 2018-03-30
ZA201603117B (en) 2020-05-27
EP3074414A1 (en) 2016-10-05
WO2015077780A1 (en) 2015-05-28
CA2931064A1 (en) 2015-05-28
CA2931064C (en) 2022-10-18
KR20160137945A (en) 2016-12-02
PL3074414T3 (en) 2019-12-31
AU2014352629A1 (en) 2016-05-26
MX2016006544A (en) 2016-12-12
JP2016537432A (en) 2016-12-01
US20170022247A1 (en) 2017-01-26
ES2728870T3 (en) 2019-10-29
BR112016012002A2 (en) 2017-09-19
JP6517833B2 (en) 2019-05-22
TR201905218T4 (en) 2019-05-21
US10351590B2 (en) 2019-07-16
AU2014352629B2 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
UA116648C2 (en) FUMARATS AS A PRODUCT AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
TN2015000278A1 (en) Autotaxin inhibitors
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MX2020009780A (en) Autotaxin inhibitor compounds.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2016016666A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
TW201613901A (en) New compounds
PH12016500094A1 (en) Autotaxin inhibitors
MX2015010125A (en) Pyridazinone-amides derivatives.
GB201209613D0 (en) New compounds
MX2014008705A (en) Tricyclic sulfone compounds and methods of making and using same.
PH12017500315A1 (en) Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection
MX356755B (en) Fumigillol type compounds and methods of making and using same.
TR201910866T4 (en) Combined preparations for cancer treatment.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX357284B (en) Quinone compounds for treating ape1 mediated diseases.
MX2016006544A (en) Withanolides useful for the treatment of neurodegenerative diseases.
MX2015005732A (en) Tricyclic compounds and methods of making and using same.
MX2015013755A (en) Pharmaceutical formulation for use in the treatment and/or prevention of restenosis.
MX2015005733A (en) Tricyclic compounds for use in the treatment and/or control of obesity.
MX2017009608A (en) Anti-cancer compounds.
IN2013MU03118A (en)

Legal Events

Date Code Title Description
FG Grant or registration